|
Tecentriq (atezolizumab)
|
|
Direct Healthcare Professional Communication about Recormon (epoetin beta)
|
|
Novartis information on ophthalmic products based on Safety Notice provided by Becton Dickinson Company
|
|
Supply situation for Actemra IV - outlook for 2022
|
|
Kadcyla: Educational Information For Healthcare Professional
|
|
Important information about MabThera
|
|
ALECENSA (alectinib), Warning and Precaution and Specific Dose Modification Guidance for Management of Haemolytic Anaemia
|
|
Champix (varenicline)
|
|
Brolucizumab (VSIQQ)
|
|
CellCept (mycophenolate mofetil): information about risks to the unborn baby
|
